Decision Diagnostics, Corp. DECN
We began tracking DECN just under three weeks ago, back on the morning of March 19th. The stock caught our attention after announcing that it was working on a rapid-result COVID-19 test. Subsequent to that point in time, it was trading for as little as .056/share.
Yesterday, following another tag in our extended watchlist, and as an update on the company’s coronavirus test was provided (excerpt and link below), the stock reached some very impressive new highs. It’s not the first coronavirus related play we’ve scored on, and it won’t be the last.
DECN ran 216% intraday from .125 to a new high of .395. From our initially observed low from the week before last, the stock has now exhibited an upswing of 605%
Decision Diagnostics Corp. (OTC PINK:DECN) through its subsidiary Pharma Tech Solutions, Inc. …announces today that the company has received the Pre-EUA Acknowledgement letter from the U.S. FDA for device (serial number) PEUA200232, GenViro Covid-19 Screening Kit. This grant by the FDA is a major milestone in our GenViro!™ Covid-19 test kit development (>>View Full PR)
Johnson & Johnson JNJ – Recap
After seeing success with a number of different targets within the JNJ chain over the past week and change, we rolled our potential strike prices up to the JNJ Weekly $140-142 Calls yesterday morning.
Being one of the lead candidates for potentially developing an effective COVID-19 vaccine, it puts JNJ in a somewhat unique position, as experts have repeatedly stated that the world cannot begin to fully recover until a viable vaccine is being widely administered sometime next year.
Our move to the $140-142 Calls proved prudent yesterday, as early activity provided the following intraday opportunities:
JNJ Weekly $140-142 Calls
$140: .89-2.88 (+224%)
$141: .62-2.31 (+273%)
$142: .43-1.67 (+288%)
LEVI 04/17 $12-13 Calls
SGH 04/17 $22.50-25 Calls
BIEI, MBRX PINS, BNGO, SONN, EFC, NYMT